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ABSTRACT 
Introduction: Acute bupropion (BUP; dopamine/noradrenaline reuptake inhibitor) 
administration significantly improved time trial performance and increased core 
temperature in the heat (30°C). Purpose: The present study was performed to examine 
the effect of a dopaminergic reuptake inhibitor on exercise capacity and 
thermoregulation during prolonged exercise in temperate and warm conditons. 
Methods: Eight healthy well-trained male cyclists participated in this study. Subjects 
ingested either a placebo (PLAC; lactose; 20mg) or Ritalin (RIT; methylphenidate 
(MPH); 20mg) one hour before the start of exercise in temperate (18°C) or warm (30°C) 
conditions and cycled for 60 min at 55% Wmax, immediately followed by a time trial 
(TT; pla18 and rit18; pla30 and rit30) to measure exercise performance. Results: Ritalin 
did not influence TT performance at 18oC (P=0.397). TT was completed 16% faster in 
rit30 (38.1±6.4min) than in pla30 (45.4±7.3min; p=0.049). Power output was higher in 
rit30, compared to pla30 (p<0.05). In the heat Tcore was significantly higher at rest 
(p=0.009), at the start of exercise and throughout rit30 (p<0.05). Throughout rit30 heart 
rates were significantly higher (p<0.05). Prolactin concentrations decreased after one 
hour cycling in 18°C (p=0,036) and at rest in 30°C (p=0,007) after RIT administration. 
Conclusions: These results show that RIT has a clear ergogenic effect that was not 
apparent in 18°C. The combination of a dopamine reuptake inhibitor and exercise in the 
heat clearly improved performance and appeared to increase metabolic heat production, 
suggesting an important role for dopamine in the fatigue process.  
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Introduction 
 
Paragraph 1 It is well documented that exercise performance is negatively influenced 
in high environmental temperatures (3, 20). The capacity to exercise in the heat is 
thought to be primarily limited by thermoregulatory and fluid balance factors (8), and it 
has further been suggested that the central nervous system (CNS) may become 
important in the development of fatigue when body temperature is significantly elevated 
(15). Previous work conducted by Gonzalez-Alonso et al (6) concluded that a high 
internal body temperature (Tcore) per se causes fatigue in trained subjects during 
prolonged exercise in uncompensable hot environments. Hyperthermia has been 
demonstrate to exert a profound effect on the CNS, with a reduction in maximal muscle 
activity (17), altered EEG brain activity (16) and increased perceived exertion (18) 
reported when body temperature is elevated. These factors could all contribute to the 
reduction in performance seen when exercise is undertaken in the heat. 
 
Paragraph 2 In a series of studies, Piacentini and colleagues (12, 21, 23, 24) failed to 
modify performance of a 90 minutes time trial in normal ambient temperatures (18°C), 
through the manipulation of central neurotransmission. However, the authors detected 
different hormonal responses depending on the neurotransmitter system triggered by the 
reuptake inhibitor. The neuroendocrine response to exercise suggested that the drugs did 
indeed produce a central effect, despite failing to influence performance. These data 
raise several questions: are the neurotransmitters targeted in these studies involved in 
fatigue during exercise, was the action of these drugs sufficient to bring about changes 
in performance or was the protocol employed appropriate to detect changes in 
performance resulting from these interventions? 
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Paragraph 3 In a recent study Watson et al (30) examined the effects of Bupropion 
(BUP; a dual dopamine/noradrenaline reuptake inhibitor) not only in temperate, but also 
in warm environmental conditions. The major finding was that subjects completed the 
time trials in the heat 9% faster when BUP was taken, an effect that was not apparent in 
18°C. Seven out of nine subjects also attained body core temperatures exceeding 40°C, 
implying that BUP may dampen or override hyperthermia-induced inhibitory signals 
arising from the CNS to stop exercising, potentially increasing the risk on developing 
heat illness. Since the increase in central catecholaminergic neurotransmission may, in 
part, attenuate the loss of performance when exercise is performed in warm 
environmental temperatures (30) and DA is involved in both motor behaviour and 
motivation (14), it would be interesting to elucidate the specific role of DA in this 
process. Amphetamines are known to increase extracellular DA and have been 
associated with flushing, sympathetic activation, increased metabolic rate, as well as 
clinical hyperthermia (4). 
 
Paragraph 4 Ritalin (RIT), an amphetamine – like stimulant, is a well-known DA 
reuptake inhibitor (5) that is widely administered to treat children with Attention Deficit 
Hyperactivity Disorder (ADHD). The active substance of RIT is methylphenidate 
(MPH), which occupies the DAtransporter (DAT; 28) and has a five times higher 
affinity for the DAT than for the NAtransporter (NAT; 9, 19). To our knowledge, there 
are no data available on the effects of RIT administration on exercise performance and 
thermoregulation during prolonged exercise in both normal and high ambient 
temperatures, even though it is administered to thousands of patients around the world. 
Therefore, the purpose of the present study is to examine the effect of RIT on exercise 
capacity and thermoregulation. We hypothesise that acute administration of the DA 
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reuptake inhibitor RIT will enhance exercise performance and will influence metabolic 
heat production during exercise in temperate and hot environmental conditions.   
 
 
Methods 
 
Paragraph 5 Subjects. Eight healthy males (age 26  5y; Ht 1.82  0.06m; mass 77.9  
6.4kg; Wmax 361  18W) participated in this investigation. All subjects were well-
trained cyclists or triathletes, but were not accustomed to exercise in a warm 
environment at the time of the study. Prior to the start of the study all volunteers 
received written information regarding the nature and purpose of the experimental 
protocol. Following an opportunity to ask any questions, a written statement of consent 
was signed. The protocol employed was approved by the Research Council of the Vrije 
Universiteit Brussel, Belgium. 
 
Paragraph 6 Experimental protocol. The experimental protocol used in this study is 
identical to the protocol used by Watson et al (30), therefore we will address it briefly. 
All subjects completed a preliminary maximal exercise test, a familiarisation trial and 4 
experimental trials. The preliminary trial consisted of continuous incremental cycle 
exercise to volitional exhaustion and was used to determine the power output required 
to elicit 55 % and 75 % of maximal workload (Wmax). A familiarisation trial was 
undertaken to ensure the subjects were accustomed to the procedures employed during 
the investigation and to minimise any potential learning or anxiety effects. This trial 
was performed in temperate environmental conditions and was identical to the 
experimental trials in all respects. Experimental trials were undertaken in either 
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temperate (18oC) or warm (30oC) conditions (trials are referred to as: placebo 18°C 
‘pla18’, placebo 30°C ‘pla30’, Ritalin 18°C ‘rit18’ and Ritalin 30°C ‘rit30’), with 
relative humidity maintained between 50 – 60 % in both conditions. All subjects had to 
complete all experimental trials, which were separated by at least 7 days to minimise the 
development of heat acclimation and to ensure drug washout. Subjects were instructed 
to record dietary intake and physical activity during the two days before the first trial, 
and to replicate this in the two days prior to the subsequent experimental trials. No 
exercise or alcohol consumption was permitted in the 24 hours before each trial.   
 
Paragraph 7 Subjects entered the laboratory in the morning approximately 90 minutes 
after consuming a standardised breakfast that included 500 mL of plain water. Nude 
post-void body mass was measured and an indwelling venous cannula was introduced 
into a superficial forearm vein to enable repeated blood sampling at rest and during 
exercise. Subjects inserted a rectal thermister (Gram Corporation LT-8A, Saitama, 
Japan) 10 cm beyond the anal sphincter for the measurement of core temperature. 
Surface skin temperature probes (Gram Corporation LT-8A, Saitama, Japan) were 
attached to four sites (chest, upper arm, thigh and calf) to enable the determination of 
weighted mean skin temperature (25) and a heart rate telemetry band (Polar Accurex 
plus, Kempele, Finland) was positioned. Subjects were dressed in only cycling shorts, 
socks and shoes for all trials. 
 
Paragraph 8 Subjects then entered a climatic chamber maintained at the appropriate 
environmental conditions and rested in a seated position for 15 minutes. During this 
period temperatures and heart rate were recorded at 5 minute intervals and a resting 
venous blood sample was drawn immediately before the start of exercise. The exercise 
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protocol consisted of 60 minutes constant load exercise at a workload corresponding to 
55 % Wmax, followed by a time trial (TT) to measure exercise performance. There was a 
1 to 2 minute delay between the end of the constant load exercise and the beginning of 
the TT, to program the ergometer (Lode Excalibur Sport, Groningen, Holland). The TT 
required the subjects to complete a predetermined amount of work equal to 30 minutes 
at 75 % Wmax as quickly as possible (10). Subjects began the TT at a workload 
corresponding to 75 % Wmax, but were free to increase or decrease their power output as 
desired from the outset. During the TT a computer program displayed a bar indicating 
the percentage of total work completed to give the subject an indication of their 
progress. Throughout the protocol no feedback was provided regarding time lapsed, 
power output, pedal cadence or heart rate. During exercise subjects had ad libitum 
access to plain water. 
 
Paragraph 9 Core and skin temperatures and heart rate were recorded at 5 minute 
intervals during exercise. Ratings of perceived exertion (RPE; 2) and thermal stress 
(assessed using a 21-point scale ranging from unbearable cold to unbearable heat) were 
assessed every 15 minutes during the initial 60 minutes and at 10 minute intervals 
during the TT. Venous blood samples were drawn after 60 minutes of constant load 
exercise and at the end of the TT. Following the completion of the TT, subjects returned 
to a seated position where recovery was monitored for 15 minutes and a further blood 
sample was obtained. The probes and cannula were then removed and nude body mass 
was then re-measured to allow the estimation of sweat losses. 
 
Paragraph 10 Drugs. Subjects ingested 20mg RIT or a placebo (PLAC: lactose) one 
hour before the start of exercise. This rather low dose (the maximum dose for an adult is 
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1,3mg/kg spread over an entire day) was chosen due to the unknown reactions to the 
combination of extreme heat stress and exercise. The treatment was randomised and 
administered in double-blind crossover manner. RIT and PLAC capsules were prepared 
by an independent pharmacy to appear indistinguishable with regard to dimensions, 
weight and colour.  
 
Paragraph 11 Blood collection and analysis. Venous blood samples were drawn 
directly into pre-cooled vacutainer tubes (BD Vacutainer, Plymouth, UK). 10 mL 
samples were collected into a plain tubes and left to clot for 1 hour at room temperature 
before centrifugation. The resulting serum was stored at –20oC for the determination of 
prolactin (PRL; Roche Diagnostics, Mannheim, Germany), cortisol (Diasorin, 
Stillwater, USA) and growth hormone (GH; Pharmacia & Upjohn Diagnostics, Uppsala, 
Sweden). Samples for plasma adrenocorticotropic hormone (ACTH) and beta-endorphin 
(Nichols Institute Diagnostics, CA, USA) were collected into 4.5 mL tubes containing 
K3EDTA. An additional 7.5mL was added to lithium heparin. A 0.5 mL aliquot of 
whole blood was extracted and used for the determination of haemoglobin and 
haematocrit, with these used to estimate percent changes in plasma volume relative to 
the pre-exercise sample. Sodium metabisulphate (5 mg) was then added to the 
remaining whole blood prior to centrifugation. 
 
Paragraph 12 Statistical Analysis. Data are presented as means  standard deviation 
(SD), unless otherwise stated. To evaluate differences in TT performance, 2-factor 
(temp x drug) repeated measures ANOVA were employed. Data collected over time 
were analyzed using 3-factor (temp x drug x time) ANOVA with repeated measures. 
Pairwise differences were identified using Tukey’s post-hoc test as appropriate. 
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Statistical significance was accepted at P < 0.05. To improve the clarity of figures, 
differences present between environmental conditions are described in the text. 
 
 
Results 
 
Paragraph 13 All subjects completed all the experimental trials. Exercise performance 
was significantly influenced by environmental temperature (p<0.001; Fig. 1), with 
subjects taking longer to complete the predetermined amount of work in the heat. Acute 
RIT supplementation increased exercise performance in warm (p=0.049) but not 
temperate (p=0.397) conditions. Subjects finished 16% faster, when RIT was ingested 
compared to the PLAC (pla30: 45’24” ± 7’18”, rit30: 38’06” ± 6’24”; Fig. 1). 
 
INSERT FIG. 1 HERE 
 
Paragraph 14 As the TT required the completion of a predetermined amount of work, 
the time taken to complete the protocol was directly related to the power output 
maintained throughout this period. After PLAC treatment the power output was 
significantly higher in the temperate trials in comparison with the trials in warm 
environmental conditions (p=0.010), this was only obvious after 30min in the time trial 
after RIT administration (p=0.016). In the 30°C trials, in contrast with the trials in 18°C 
(Fig. 2A), a difference in power output was apparent between the PLAC and RIT trial 
from the start of exercise till near completion of the target amount of work (p<0.045; 
mean power output in rit30: 226 ± 37W, in pla30: 196  ± 35W; Fig. 2B). 
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INSERT FIG. 2 HERE 
 
Paragraph 15 Core temperature increased significantly after 5 and 10 minutes of rest 
following RIT administration in the heat (p=0.013; Fig. 3), while in temperate 
conditions no such effect was present (p=0.360). Exercise produced a gradual increase 
in core temperature in all trials (p<0.001; Fig. 3). Ambient temperature and RIT both 
influenced Tcore during exercise. Tcore rose significantly higher in rit30 then in the 
pla30 after 5, 15 and 20 minutes of fixed intensity exercise (p<0.039) and at all times 
(p<0.043) except the 15 minutes marker (p=0.052) during the TT and the recovery. 
Tcore rose till 40.0 ± 0.6°C at the end of exercise in rit30. During the trials in temperate 
conditions significant increases in Tcore were observed only after 5 and 20min in 
rit18TT (p=0.022 and 0.025 respectively) in comparison to pla18TT, reaching a 
maximum average temperature of 39.5 ± 0.6°C at the end of exercise. No differences in 
weighted mean skin temperature were obvious between PLAC and RIT. Skin 
temperature increased during exercise in all conditions (p<0.001), reaching a plateau 
after 15min  in pla30 and rit30 and after 20min in pla18 and rit18. 
 
INSERT FIG. 3 HERE 
 
Paragraph 16 Ambient temperature increased mean heart rates in the corresponding 
trials (pla18: 145 ± 8 b/min and pla30: 152 ± 10 b/min; rit18: 151 ± 9 b/min and rit30: 
160 ± 9 b/min; Fig. 4). Heart rates after 40min fixed intensity exercise were 
significantly higher in the rit30 compared to the pla30 (pla30 170 ± 7 b/min and rit30 
178 ± 12 b/min). During the TT, drug treatment induced significant increases in heart 
rate in normal temperature after 15 (p=0.025) and 25 minutes (p=0.033) and at the end 
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of the TT (p=0.009). In addition, the drug treatment significantly increased heart rate at 
every time point during exercise in the heat (p<0.046; Fig. 4). During recovery in 18°C 
heart rate was only significantly elevated after 5min in the RIT trial (p=0.024), while 
this was the case at every time point in the heat (p<0.046).  
 
INSERT FIG. 4 HERE 
 
Paragraph 17 Ratings of perceived exertion (RPE) were similar between PLAC and 
RIT treatment in temperate conditions (Fig. 5A). During the initial 60min of fixed 
intensity exercise in the heat RPE rose significantly higher in the PLAC treatment 
(pla30: 16.6 ± 1.3; rit30: 14.5 ± 1.7; p=0.034; Fig. 5B). In the TT this difference 
disappeared.  The subjects’ ratings of thermal stress (TS) were elevated by the higher 
ambient temperature (p<0.001), but not influenced by the drug treatment. Both RPE and 
TS scores increased during exercise (p<0.001). The loss of body mass after exercises, 
corrected for fluid intake, was significantly higher in the warm compared to the 
temperate trials (pla18: 2.44 ± 0.50l and pla30: 3.33 ± 0.62l; rit18: 2.37 ± 0.27l and 
rit30: 3.21 ± 0.58l; p=0.004), but no effect of RIT on sweat losses was found. 
 
INSERT FIG. 5 HERE 
 
Paragraph 18 All measured hormone concentrations rose significantly during exercise 
in all trials (p<0.025). Circulating serum PRL levels were influenced by drug 
administration and ambient temperature. In temperate conditions there was a trend for 
the PRL concentration to be decreased at rest in rit18 (p=0.066). After 60min of fixed 
intensity exercise the PRL concentration was significantly lower in rit18 in comparison 
    
12
to pla18 (p=0.036;  pla18: 8.0 ± 2.8ng/ml; rit18 6.6 ± 2.2ng/ml; Fig. 6A). In the heat the 
resting PRL concentration was significantly lower after RIT administration (p=0.007), a 
trend towards a lower PRL concentration was visible after 60min fixed intensity 
exercise (p=0.065). In temperate conditions plasma ACTH levels were significantly 
elevated at rest after RIT administration (p=0.036; pla18: 21.6  ± 7.4ng/l; rit18: 26.1 ± 
5.7ng/l; Fig. 6B). No differences in ACTH concentrations between drug treatments 
were apparent in the heat. Growth hormone concentrations were significantly lower 
after 60min fixed intensity exercise in the heat when RIT was taken (p=0.034; pla30: 
18.8  ± 11.3ng/l; rit30: 13.3 ± 8.3ng/l; Fig. 6C), while no differences appeared in 
temperate conditions. No differences in cortisol (Fig. 6D) and beta-endorphin levels 
were detected between trials (Fig. 6E). 
 
INSERT FIG. 6A,B,C, D, E HERE 
 
Discussion 
 
Paragraph 19 The current study investigated the effects of acute oral administration of 
RIT (a DA reuptake inhibitor) on exercise performance, thermoregulation and hormonal 
responses to prolonged exercise in both temperate and warm environments. The 
improved exercise performance in the heat and increased core temperature and heart 
rate in both normal and warm conditions are in line with the results previously found by 
Watson et al (30) after BUP administration, which also enabled the maintenance of a 
higher power output during a TT in warm conditons. It appears that this response is 
accompanied by  an increased core temperature and heart rate, but with the same 
perception of effort and thermal stress. Similarly these and other studies that used 
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nutritional and pharmacological manipulations of catecholaminergic neurotransmission 
confirmed the lack of performance improvements in 18°C (13, 21, 24, 27, 30), 
suggesting that dopaminergic neurotransmission may only have a significant role in 
fatigue when exercise is undertaken in warm environmental temperatures.  
 
Paragraph 20 The combination of MPH, that has a potent dopaminergic activity, and 
high ambient temperatures, increased core temperature at rest in the heat. The 
mechanism behind this increase is not completely clear, possibly an increase of the 
metabolic rate causes the increase in core temperature (4). Malberg & Seiden (11) 
reported that the effect of MDMA on body temperature was influenced by ambient 
temperatures; rats given MDMA in 20°C developed hypothermia, whereas those given 
MDMA in 26-30°C developed hyperthermia. Additionally, most studies investigating 
the effects of amphetamines point out its thermogenic effect (4, 7).  
 
Paragraph 21 In the present study 4 out of 8 subjects reached a core temperature above 
40°C in the rit30, with one subject even exceeding 41°C after exercise, while there was 
only one subject that had 40.0°C at the end of the TT in pla30. There is a clear increase 
in metabolic heat production during the TT in rit30, with a greater rate of rise in core 
temperature seen during this trial. This may have resulted from an increased drive to 
perform and consequently higher power outputs at every time point except the 15 
minutes marker in comparison to pla30. This result appears remarkable as we 
administered a rather low dose (20mg) of MPH, given the maximal therapeutic dose is 
set at 60mg/day. It is important to note that even at this low dose there is a potentially 
increased risk of developing heat illness, when performing hard exercise in warm 
conditions. Interestingly, the perceptional response to an increased core temperature and 
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heart rate seems to be dampened by RIT, as RPE was significantly higher in pla30 after 
60 minutes of fixed intensity exercise and no changes in thermal stress were found. 
These findings might in part result from increased drive to continue exercise following 
RIT administration, given the role of dopamine in feelings of arousal and motivation, as 
was previously stated by Volkow and colleagues (29). As in the BUP trial in the heat 
(30), it appears that RIT administration, even at low doses, might result in an inhibition 
of signals arising from the CNS to cease exercise because of hyperthermia, and enable 
subjects to maintain a high power output even at that time. 
 
Paragraph 22 Hormonal responses to exercise after manipulation of catecholaminergic 
neurotransmission have been studied before. BUP has been reported to influence 
ACTH, cortisol, beta-endorphin values at rest and during prolonged exercise (21); these 
changes were, in part, attributed to the noradrenergic properties of the drug. Watson et 
al (30) reported increased plasma ACTH and cortisol concentrations at rest and ACTH 
levels during exercise after BUP administration, while no influence on GH and PRL. 
Changes in circulating PRL concentrations have previously been employed in defining 
serotonergic activity, but its reliability has been questioned (12). Ben-Jonathan (1) 
established that hypothalamic DA release inhibits PRL secretion from the anterior 
pituitary. Slattum et al (26) also found (+)-amphetamine suppressed PRL secretion in 
human subjects and a rat study by Piacentini et al (22) resulted in decreased PRL 
concentrations after BUP administration, indicating an important role for the DA 
system.  The present study agrees with these findings, since PRL concentrations showed 
significant decreases after 60min in rit18 compared to pla18 and at rest between rit30 
and pla30. At rest in 18°C (p=0.066) and after sixty minutes in the heat (p=0.065) 
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significance was marginally missed, indicating a strong effect of MPH on PRL 
concentrations, even at a low dose of the drug.  
 
Paragraph 23 Although DA is reported to have an inhibitory effect on most pituitary 
hormones except for GH (21), the present study showed a significantly lower GH 
concentration after 60min of exercise in rit30.  
In 18°C there is some evidence for a catecholaminergic effect of RIT, since plasma 
ACTH concentrations are higher at rest in rit18. The higher ACTH concentration 
remained during exercise but due to large intra-subject variations no significance could 
be proven. 
  
Paragraph 24 In conclusion, acute RIT administration resulted in a significant 
improvement in the time to complete a predetermined amount of work in a warm 
environment. This ergogenic effect was not apparent at 18°C. Core temperature in rit30 
increased to a mean of 40,0 ± 0.6°C with 4 out of 8 subjects reaching core temperatures 
above 40°C and 1 subject attaining 41°C after exercise. However, no differences 
between PLAC and RIT were apparent in perceived thermal stress, and after sixty 
minutes of exercise in the heat the perceived exertion was significantly higher in the 
PLAC situation. These results suggest that RIT exerts equal or even more pronounced 
effects on exercise performance,  metabolic heat production and hormonal responses 
than previously demonstrated with BUP. 
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Figure legends 
 
Fig. 1: Time trial time in the four experimental trials (mean ± SD). 
* denotes a significant difference between the PLAC and the corresponding time 
point on the RIT trial (p<0.05). 
 
Fig. 2: Time trial power output in temperate (A) and warm (B) conditions (mean ± SD).  
            * denotes a significant difference between the PLAC trial and the corresponding 
time point on the RIT trial (p<0.05). 
 
Fig. 3: Core temperature in temperate (A) and warm (B) conditions (mean ± SD).  
* denotes a significant difference between the PLAC trial and the corresponding 
time point on the RIT trial (p<0.05). 
§ denotes a significant difference between the PLAC trial and the  
corresponding time point on the RIT trial (p<0.05). 
 
Fig. 4: Heart rates in temperate (A) and warm (B) conditions (mean ± SD).  
* denotes a significant difference between the PLAC trial and the corresponding 
time point on the RIT trial (p<0.05). 
§ denotes a significant difference between the PLAC trial and the  
corresponding time point on the RIT trial (p<0.05). 
 
Fig. 5: RPE scores in temperate (A) and warm (B) conditions (mean ± SD).  
            * denotes a significant difference between the PLAC trial and the corresponding 
time point on the RIT trial (p<0.05). 
 
Fig. 6: PRL (A), ACTH (B), GH (C), cortisol (D)  and B-end (E) concentrations at rest,  
after 60 minutes, at the end of the time trials and after 15 minutes recuperation  
(means ± SD).  
* denotes a significant difference between the PLAC trial and the corresponding 
time point on the RIT trial in 18°C (p<0.05).  
§ denotes a significant difference between the PLAC trial and the corresponding 
time point on the RIT trial in 30°C (p<0.05). 
